Wockhardt swings to profit as operating margin reaches 23.32%
Revenue grew 29.88% year on year, while costs rose 8.98%; other income accounted for 35.45% of pre-tax profit.
Filed 04 May 2026, 19:00 IST · after market close · Wockhardt Ltd (WOCKPHARMA)
Key takeaways
- Consolidated operating margin expanded 14.71 percentage points year on year as revenue grew 29.88% while expenses rose 8.98%.
- Net profit recovered to Rs 164 cr from a loss of Rs 45 cr, but other income contributed 35.45% of pre-tax profit.
- The stock rose 7.86% on the first trading day after the results, more than twice its 3.13% median move after the past eight results.
Price around the results
Revenue growth translated into a sharp profit recovery
Wockhardt reported consolidated revenue growth of 29.88% year on year, while expenses increased 8.98%, lifting operating profit growth to 251.56%. The operating margin widened 14.71 percentage points to 23.32%, and net profit recovered from a loss of Rs 45 cr to Rs 164 cr. Sequentially, revenue rose 8.67% and operating profit increased 27.12%.
Margin rebound followed slower cost growth
The sequential margin recovery of 3.39 percentage points came as revenue grew 8.67% while expenses rose 4.08%; interest expense also fell 16.67%. The quarter reversed the margin decline seen from 22.76% in Q2FY26 to 19.93% in Q3FY26, taking the margin to 23.32% in Q4FY26. This was broadly in line with the 23.38% median operating margin for 48 reported healthcare peers, at a gap of 0.06 percentage points below the median.
Other income remains material to reported profit
Other income rose to Rs 67 cr from Rs 15 cr in both the year-ago and preceding quarters, and represented 35.45% of pre-tax profit. That makes the net-profit recovery less purely operational than the operating-profit improvement. The tax rate increased 4.27 percentage points sequentially to 13.23%, so the quarter's profit growth was not driven by a lower tax rate.
Management links the next phase to launches and cost projects
Management said it plans to enter 7-8 markets with a high carbapenem-resistance burden over the next 18-24 months, alongside planned Zaynich launches in the US, India, Europe and emerging markets. The company said it had implemented more than 50 manufacturing cost-management projects and was building an integrated launch architecture. It also said the India go-to-market plan targets at least 80% patient-pool coverage, while its reported covered-market share is 18%.
The market reaction was unusually positive for this stock
The stock gained 7.86% on the first trading day after the results and was up 20.48% after one trading day. That was well above the 3.13% median absolute move following the past eight results, when the stock rose after five and fell after three. The first-day move was therefore larger and more positive than its recent results-day pattern.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹965 cr | ₹888 cr | +8.67% | +29.88% |
| Other income | ₹67 cr | ₹15 cr | +346.67% | +346.67% |
| Expenses | ₹740 cr | ₹711 cr | +4.08% | +8.98% |
| Operating profit | ₹225 cr | ₹177 cr | +27.12% | +251.56% |
| Operating margin (%) | 23.32% | 19.93% | — | — |
| Interest | ₹50 cr | ₹60 cr | -16.67% | +4.17% |
| Depreciation | ₹53 cr | ₹65 cr | -18.46% | +0.00% |
| Profit before tax | ₹189 cr | ₹67 cr | +182.09% | — |
| Tax | ₹25 cr | ₹6 cr | +316.67% | +8.70% |
| Net profit | ₹164 cr | ₹61 cr | +168.85% | — |
| EPS (₹) | ₹10.23 | ₹3.61 | +183.38% | — |
Operating margin of 23.32% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +7.86% | +8.22% |
| Next session | +20.48% | — |
| 5 sessions | +10.20% | +13.27% |
| 15 sessions | +19.31% | — |
| 30 sessions | +41.95% | — |
Volume on the results session was 27.44× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company’s objectives for the next two years include growth acceleration and sustainable operational excellence enabled by AI.
- The company plans to enter 7-8 key markets with high carbapenem-resistance burden in the next 18-24 months.
- The company aims for registration and launch in Latin America, Eurasia, GCC and South/Southeast Asia markets.
- The India go-to-market plan targets at least 80% patient-pool coverage.
Expansion
- Zaynich is planned for launch in the US, India, Europe and emerging markets.
New products
- Zaynich is planned for launch across the US, India, Europe and emerging markets.
- Miqnaf is intended to extend reach and add indications.
New initiatives
- The company implemented more than 50 projects under its corporate-wide manufacturing cost-management improvements.
- The company is establishing an integrated launch architecture that is competency and capability heavy but operationally light.
- Building real-world evidence and ensuring right usage in the right patients is the India launch strategy.
- The company plans multi-stakeholder partnerships for antimicrobial-resistance management excellence.
Competition
- The India business reports 18% covered market share.
Problems & risks
- The company says standard antibiotics increasingly fail, creating an urgent unmet clinical need.
What to watch
- Whether operating margin holds above 23.32% after the Q4FY26 rebound.
- Whether other income remains below the 35.45% share of pre-tax profit reported this quarter.
- Progress on management's stated plan to enter 7-8 high carbapenem-resistance markets over 18-24 months.